BCG cell wall skeletons (SK) derived from BCG cell walls (CW) by treatment with proteolytic enzymes and organic solvents were tested for their potency to cause regression of a transplanted guinea pig hepatoma. On a weight basis, SK were as effective as CW in causing tumor regression, and they, as well as purified protein derivative of mycobacteria, provoked delayed cutaneous hypersensitivity reactions in animals immunized with CW or with SK. On a weight basis, CW were more active than SK in eliciting delayed cutaneous hypersensitivity in sensitized guinea pigs whether the animals were immunized with CW or with SK. In unimmunized animals the inflammatory response to intradermally administered CW was greater than that evoked by SK. CW and SK provoked delayed cutaneous hypersensitivity reactions of similar strength in animals immunized with living BCG. This study provided no compelling reasons for using SK instead of CW in clinical trials of cancer treatment by mycobacterial vaccines.
BCG is being widely used to treat experimental and clinical cancer (2) . Nonviable but immunotherapeutically active mycobacterial preparations might be useful clinically, because one possible undesirable effect of administering living BCG intralesionally to cancer patients is systemic BCG infection (5a) . Oil droplet emulsions of BCG and BCG cell wall skeletons (SK) have been reported to be of value in the treatment of certain human cancers (6; H. Cohen and A. Bekierkunst, submitted for publication). SK were obtained from BCG cell walls (CW) by digestion with proteolytic enzymes and exhaustive extractions with organic solvents (1) . It has been claimed that CW were more effective than SK in causing regression of the line 10 guinea pig hepatoma (4, 5, 9) . It was not clear, therefore, why SK rather than CW were used in a study of the immunotherapy of human melanoma (6) .
The choice of SK in this trial may have been based on the hope that it would be less immunogenic than CW and therefore safer. The studies reported here were undertaken to compare (i) the efficacy of CW and SK vaccines in producing regression of the line 10 guinea pig hepatoma and (ii) their immunogenicity as judged by delayed cutaneous hypersensitivity (DCH) .
BCG CW lot 217b and BCG SK lot 176 were obtained from E. Ribi, Rocky Mountain Laboratory, Hamilton, Mont. The grinding method for preparing the mycobacterial vaccines has been described previously (8) . Each vaccine containing a given concentration of CW or SK was prepared separately and identically so that all vaccine preparations contained the same amount of oil (3%) and Tween 80 (0.2%) and differed only in CW or SK content. Emulsified vaccines were infiltrated through a 27-gauge needle into the growing tumor in 0.4-ml volumes. All experiments were done with tumor line 10, an ascitic variant derived from a hepatocarcinoma induced by diethylnitrosamine in a strain 2 guinea pig. Inoculation of 106 tumor cells intradermally (i.d.) resulted in progressive i.d. tumor growth, and by 1 week tumor cells were present in the draining lymph nodes; guinea pigs usually died 2 to 3 months later (10) . Animals were treated by administration of a single intralesional injection of CW or SK vaccine 7 days after tumor implantation when the average diameter of the tumors was 9 mm. A control group consisted of untreated animals ( Table 1 ). In each of two separate experiments, comparable cure rates were produced by both vaccines. In the first experiment tumors regressed completely in all animals treated with 0.2 mg or more of CW or SK; five of six guinea pigs were cured by 0.05 mg of CW. In the second experiment, 0.8 mg of either vaccine cured 6 of 6 guinea pigs, but in only 6 In addition to determining the relative therapeutic efficacy of CW and SK vaccines, we tested Fig. 1 and 2) . No skin reactions were found in the normal animals challenged with PPD (up to 0.002 mg) or SK (up to 0.05 mg). CW induced a mild inflammatory reaction in control animals at a dose of 0.05 mg (3.2 ± 1.8 mm in diameter). CW and SK vaccines at the doses used for immunization were comparably immunogenic. The degree of skin reactivity elicited in these animals by each dose of CW in saline was significantly greater than that found with an equivalent dose of SK (Fig. 1) . Similar results were found in animals presensitized with 0.8 mg of CW or SK vaccine (Fig. 2) . The skin reaction to these mycobacterial antigens was also tested in 10 guinea pigs (strain 13) presensitized with living BCG (Fig. 3) . Ten normal animals served as controls. As in the previous experiment, 0.05 mg of CW produced mild inflammation in the normal animals. In immunized animals the intensity of the skin reaction produced by CW was not significantly different from that found with an equivalent dose of SK. The studies documented here showed that mycobacterial vaccines made either with BCG CW or with deproteinized and delipidated BCG CW (SK) were capable of curing all guinea pigs with a transplanted hepatoma at a time when there was local spread of disease to draining lymph nodes. It has been claimed that BCG CW had greater efficacy of tumor regression than BCG SK (4, 5, 9) . Each of these claims was based on one experiment with relatively low concentrations of BCG SK, and the reported differences among the cure rates were not statistically significant. The on September 6, 2017 by guest http://iai.asm.org/ the reactivity of CW seen in unimmunized animals contributed to the DCH reaction induced by CW in immunized animals. SK is a mycolic acid-arabinogalactan-mucopeptide complex (1) . The approximate composition of SK is 6% fatty acid, 1% protein, and 34% carbohydrate; that of CW is 20% fatty acid, 11% protein, and 28% carbohydrate (E. Ribi, personal communication). The protein remaining in SK may account for the induction of DCH to PPD.
The lack of apparent advantage of mycobacterial vaccines made with SK over those made with undegraded CW as well as the increased cost and the complexity of preparation of SK militate against the use of this agent in clinical trials of cancer immunotherapy in which the primary treatment consists of a single intratumoral infiltration of a mycobacterial vaccine.
